2Ohe Y,OHashi Y,Kubola K,et al.Randomized phase Ⅲ study of cisplatin plus gemcitabine and cisplatin plus vinorelbine for advanced non-small-cell lung cancer.Four-Arm Cooperative study in Japan.Ann Onasl,2007,18(2):317-323.
1Schiller JH, Harrington D. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer [J]. N Engl J Med, 2002, 346(2): 92-8.
2Zhou Y, Gwadry FG, Reinhold WC, et al. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time- dependen effects [ J ]. Cancer Res, 2002, 62(6): 1688-95.
3Jagasia MH, Langer CJ, Johson DH, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A multicenter phase II study[J]. Clin Cancer Res, 2001, 7(1): 68-73.
4Ikuno N, Soda H, Watanabe M, et al. Lrinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum [J]. J Natl Cancer Inst, 1995, 87(24): 1 876-83.
5DeVore RF, Johnson DH, Crawford J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 1999, 17(9): 2710-20.
6Moil K, Machida S, Yoshida T, et al. A phase II study of irinotecan and infusional cispiatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer[J ]. Cancer Chemother Pharmacol, 1999, 43(6): 467-70.
7Saito H, Kudoh S, Nakagawa K, et al. Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced non small-cell lung cancer [J]. Am J Clin Oncol, 2006, 29(5): 503-7.
8Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, eisplatin plus gcmcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Ann Cooperative Study in Japan [J]. Ann Oncol, 2007, 18(2): 317-23.
9孙燕,周际昌.临床肿瘤内科手册[M].4版.北京:人民卫生出版社,2004:106-107
10Hahn K K, Wolff J J, Kolesar J M. Pharmacogenetics and irinotecan therapy[J]. American journal of health- system pharmacy, 2006, 63(22): 2211-2217.
4Hirasawa A, Zama T,Akahane T, Nomura H, Kataoka F, Saito K,Okuho K, Tominaga E, Makita K, Susumu N, Kosaki K, TanigawaraY, Aoki D.Polymorphisms in the UGT1 Al gene predict adverseeffects of irinotecan in the treatment of gynecologic cancer inJapanese patients.J Hum Genet. 2013 Der,;58(t2):825.
5Goldberg RM, Sargent DJ, McLeod H.Leveraging learning from aphase III colorectal cancer clinical trial: outcomes,methodology, meta—analysis and pharmacogenetics. Trans Am ClinClimatol Assoc. 2010;121:21-32.